Pancreatic cancer is a malignant gastrointestinal disease with a high degree of malignancy, rapid onset, difficult treatment and poor prognosis. The age of onset is most common between 45 and 65 years old. The pathogenesis of pancreatic cancer is still unclear. The onset of pancreatic cancer is relatively insidious, and there is no special manifestation in the early stage, such as discomfort in the upper abdomen, loss of appetite and general weakness. When the symptoms appear after a few months, the disease is already in advanced stage. The whole course of the disease is short, fast developing and rapidly deteriorating. The treatment of pancreatic cancer is still based on surgery. For those who cannot be operated, palliative short-circuit surgery, chemotherapy and radiation therapy are often done. Surgical treatment should strive for early resection of cancer, but because of the difficulty of early diagnosis, the general surgical resection rate is not high. However, due to the difficulty of early diagnosis, the surgical resection rate is generally not high, and the surgical mortality rate is high and the 5-year survival rate is also low. Chemotherapy, radiotherapy and various symptomatic supportive treatments are available for late stage or pre- and post-surgical cases, but they are not effective. With the continuous improvement of radiotherapy technology, the effect of radiotherapy has been improved, often resulting in significant improvement of symptoms and prolonged survival. The prognosis for this disease is relatively poor, with an average life expectancy of about one year after the onset of symptoms and an annual survival rate of 4% for treatment with extended radical surgery. If total pancreatectomy is used survival is prolonged.